Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review
| Autor: | Rafael Ferreira Garcia, Marina Dyskant Mochcovitch, Antonio Egidio Nardi, Rafael C. Freire |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Generalized anxiety disorder Pharmacology toxicology Relapse rate Relapse prevention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Recurrence Internal medicine medicine Secondary Prevention Humans Pharmacology (medical) Relapse risk Psychiatry Clinical Trials as Topic business.industry Hazard ratio General Medicine medicine.disease Anxiety Disorders 030227 psychiatry Female business 030217 neurology & neurosurgery Anxiety disorder |
| Zdroj: | Clinical drug investigation. 37(8) |
| ISSN: | 1179-1918 |
| Popis: | Generalized anxiety disorder (GAD) is a persistent anxiety disorder with a high rate of relapse. While several trials have demonstrated the efficacy of pharmacotherapy for GAD treatment, fewer studies have investigated its efficacy in preventing symptom relapse in long-term treatment. The aim of this study is to evaluate if long-term pharmacotherapy may prevent relapses in GAD patients. This is a systematic review of the relapse prevention trials with GAD patients. Eight trials were included in this review with 5304 patients in total. All patients showed a higher risk of relapse if treatment was not maintained for at least 6 months after remission, with hazard ratios ranging from 0.12 to 0.58 and mostly moderate effect sizes (0.19–1.06). Long-term pharmacotherapy may prevent symptom relapse in GAD patients. As the relapse rate is very high, the data support the continuation of pharmacotherapy for as long as possible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink